Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI outperforms traditional tests for fatty liver diagnosis?

NCT ID NCT07305636

Diagnosis Sponsor: Tanta University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether artificial intelligence (AI) could more accurately predict liver scarring (fibrosis) in people with metabolic-associated fatty liver disease (MAFLD). Researchers compared AI models using FibroScan and clinical data against standard noninvasive scores like FIB-4 and APRI in 522 Egyptian adults. The goal is to find a better, needle-free way to diagnose fibrosis and reduce the need for liver biopsies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, AI could provide a more accurate, noninvasive way to diagnose liver fibrosis in MAFLD patients, potentially reducing the need for liver biopsies.
What could go wrong
This is a completed study with 522 participants, but AI models may not generalize to other populations or settings. The results need validation before clinical use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

522 people

The number who actually took part.

Started

May 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult Egyptian patients (≥18 years) diagnosed with metabolic associated fatty liver disease (MAFLD) according to international criteria, recruited from the outpatient clinic and FibroScan unit of the Tropical Medicine Department, Faculty of Medicine, Tanta University.

Ages

18 days and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Adults ≥18 years. Diagnosed with MAFLD according to international criteria (hepatic steatosis with metabolic dysfunction). Valid FibroScan evaluation with available LSM and CAP values. Exclusion Criteria: * Excessive alcohol intake (\>30 g/day for men, \>20 g/day for women). Chronic viral hepatitis (HBV or HCV). Autoimmune hepatitis. Known malignancy. Pregnancy. Refusal to participate.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ai (artificial intelligence) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ai (artificial intelligence) MAFLD

Contacts and locations

Locations

  • Faculty of Medicine

    Tanta, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.